GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (FRA:XE9) » Definitions » Sale Of Business

Xencor (FRA:XE9) Sale Of Business : €0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Xencor Sale Of Business?

Xencor's sale of business for the three months ended in Dec. 2023 was €0.0 Mil. It means Xencor gained €0.0 Mil from selling business. Xencor's sale of business for the trailing twelve months (TTM) ended in Dec. 2023 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Sep. 2023 ), Xencor gained the same money from selling business in Dec. 2023 (€0.0 Mil).


Xencor Sale Of Business Historical Data

The historical data trend for Xencor's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Sale Of Business Chart

Xencor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xencor Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xencor Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xencor Sale Of Business Related Terms

Thank you for viewing the detailed overview of Xencor's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor (FRA:XE9) Business Description

Traded in Other Exchanges
Address
111 West Lemon Avenue, Monrovia, CA, USA, 91016
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Xencor (FRA:XE9) Headlines

No Headlines